Tag
Finerenone significantly slows kidney function decline and reduces cardiovascular risk in hypertensive non-diabetic CKD patients, with manageable safety profiles, supporting its therapeutic role beyond diabetes.
Finerenone reduces mortality, cardiovascular, and kidney complications in cardio-kidney-metabolic syndrome patients regardless of cancer history, while patients with cancer experience greater disease burden and adverse events.
A prespecified pooled analysis of 18,991 participants found finerenone was associated with a significant reduction in sudden death across chronic kidney disease, type 2 diabetes, and heart failure populations.
A post hoc FIDELITY analysis suggests finerenone improves cardiovascular and kidney outcomes across CKM stages and may modestly shift patients toward CKM regression over time.
In FINEARTS-HF, EMPEROR-Preserved biomarker-based risk models showed good prognostic discrimination in HFmrEF/HFpEF, and finerenone’s relative treatment effect was consistent across the full baseline risk spectrum.
A breakthrough study in Science reveals that the antifibrotic drug finerenone restores fertility in premature ovarian insufficiency (POI) by reducing ovarian stromal fibrosis, enabling follicle development where hormone therapy previously f
A prespecified analysis of the FINEARTS-HF trial demonstrates that the mineralocorticoid receptor antagonist finerenone consistently reduces cardiovascular death and heart failure events in patients with HFmrEF/HFpEF, regardless of baseline
A prespecified analysis of the FINEARTS-HF trial confirms that finerenone reduces cardiovascular death and heart failure events in patients with HFmrEF and HFpEF across all symptomatic stages, offering the greatest absolute benefit to those
The FIVE-STAR trial demonstrates that while finerenone significantly reduces albuminuria in patients with T2D and CKD, it does not improve arterial stiffness (CAVI). These findings suggest that its cardiorenal benefits are primarily driven
The FIVE-STAR trial reveals that finerenone’s cardiorenal benefits stem from reducing internal kidney pressure rather than improving arterial stiffness, offering a new perspective on managing type 2 diabetes and chronic kidney disease
This clinical review synthesizes data from the FINEARTS-HF trial, highlighting finerenone’s efficacy in reducing heart failure events and cardiovascular mortality across diverse patient profiles, including those with frailty, obesity,
This analysis of the FINEARTS-HF trial identifies that while finerenone increases hypotension risk in HFmrEF and HFpEF patients, its clinical benefits persist. The study highlights key predictors of hypotension, such as low baseline blood p
In the FINEARTS‑HF trial, cardiovascular deaths comprised half of fatalities in HF with EF ≥40%, with sudden death accounting for the largest share — especially when EF was <50%. Finerenone did not clearly reduce cause‑specific mortality
The FINEARTS-HF trial demonstrates finerenone’s efficacy and safety in reducing heart failure events, improving symptoms, and lowering new-onset diabetes risk, with consistent benefits across sex, ejection fraction ranges, frailty levels, a
The FINE‑ONE Phase III trial found finerenone reduced urinary albumin-to-creatinine ratio (UACR) by 25% versus placebo in adults with type 1 diabetes and chronic kidney disease over six months, with safety broadly consistent with prior type
This analysis of the FINEARTS-HF trial reveals that finerenone reduces cardiovascular death and heart failure worsening regardless of frailty status, without increasing adverse events, supporting its use in frail patients with HFmrEF or HFp
Finerenone consistently reduces heart failure events and allows reduction of loop diuretic dosages without impacting new loop diuretic initiation, demonstrating a diuretic-sparing effect in HFmrEF/HFpEF patients.
The CONFIDENCE trial evaluates whether combining finerenone with empagliflozin more effectively reduces urine albumin-to-creatinine ratio in CKD patients with type 2 diabetes compared to monotherapy, based on baseline characteristics of 818
Combining finerenone with empagliflozin provides superior reduction in albuminuria for patients with chronic kidney disease and type 2 diabetes, without increased adverse events.
